Device Trial Radar · NCT06930677
Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200
Last checked: Nov 20, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Apr 17, 2025
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- Next Biomedical Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 16, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study in patients with knee osteoarthritis treated by embolization using NBGM200
Conditions
- Knee Osteoarthritis (Knee OA)
Interventions
embolization therapyDevice
MSK embolization
Primary outcomes
What the sponsor says the trial is designed to measure.
- Knee Injury and Osteoarthritis Outcome score (KOOS-12)Time frame: 6 months post treatment
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
University Hospital Ghent
Ghent, Belgium · Recruiting
Uz Leuven
Leuven, Belgium · Recruiting
Elisabeth-Tweesteden Hospital
Tilburg, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.